Proactive Investors - Run By Investors For Investors

Broker spotlight, including Standard Chartered, Serco, BT, IAG, Smith & Nephew, Ergomed ...

Broker spotlight, including Standard Chartered, Serco, BT,  IAG, Smith & Nephew, Ergomed ...

Is it time for Asia -focused bank Standard Chartered (LON:STAN) to depart the UK and locate its head office somewhere the regulations and levies are less onerous?

Reports over the weekend suggested it was a possibility after the higher bank levy unveiled in the Budget and new American chief executive.

And JP Morgan reckons the numbers are starting to stack up in favour.

The US broker says StanChart was the most affected by the Budget’s higher bank levy, which will reduce earnings per share by 13% in 2017. 

The group has previously indicated that the costs of a re-domicile would offset the earnings benefit but the broker calculates equity returns would rise by at least 1.3% assuming a US$2.5bn one-off charge in 2017. 

A strong case for re-domicile is now on the table, adds the broker.  

The new chef executive has also been a material positive, it adds, as it set a new price target of 1,250p compared to 1,050p previously.

JPM also raised its recommendation to ‘overweight’ from ‘neutral’.

Citigroup has also kept its ‘buy’ rating on StanChart, adding that Bill Winters' recent appointment as chief executive has put the spotlight back on an unloved stock.

“Value can be unlocked by prioritising the 3Cs: Costs, Credit and Capital, helped by macro tailwinds or the 2Ms: Margins and Modi-mania,” said the broker.

Its price target moves up to 1,300p from 1,250p and the bank is back on its Western Europe focus list.

Goldman Sachs has raised its rating on medtech and perennial bid target Smith & Nephew (LON:SN.) to ‘buy’ from ‘neutral’.

The firm has been a notable under-performer driven by a debate on whether it still is a likely acquisition target. 

Goldman says it is and sees S&N being acquired by a larger player even though are many hurdles to a potential transaction. The target is now 1300p including a bid element.

Cruise operator Carnival (LON:CCL) is cut to ‘hold’ from ‘buy’ by Deutsche Bank due to the significant moves in euro and sterling.

This may see earnings guidance this year reduced by 8% and consensus coming back by 5 to 10%. 

Long term the outlook is positive, but with only 5% upside to its £34 price target, ‘hold’ is the new stance.

Troubled outsourcer Serco (LON:SRP) gets a thumbs down from German bank Berenberg as the week begins, with the recommendation moving to 'sell' from 'hold'.

The broker cites the prospect of a long turnaround now the strategic review is completed and a "chronic" lack of free cash flow generation.

On the flipside, Societe Generale takes a shine to telecoms giant BT (LON:BT.A) repeating a ‘buy’ and hiking the target to 540p from 480p.

The heavyweight broker expects to see consensus upgrades driven by the purchase of mobile firm EE and rising synergies, after a busy but productive quarter for BT.

Also today, Liberum provides lift off to airlines operator IAG (LON:IAG) kicking the target price  to 700p from 600p, and has the stock as its top pick.

Also in the transport world but Terra firma, coach operator National Express (LON:NEX) sees US broker Jefferies lift its target price to 350p from 315p and repeats a 'buy' call.

Europa Oil & Gas (LON;EOG) has completed drilling of the Kiln Lane (EOG:50% and operator) onshore UK well. 

Wirelinelogging showed that the sandstones were water wet despite the well showing oil and gas shows while drilling. 

Broker Finncap adds that testing operations are ongoing at the Wressle well, but it takes 3.4p for Kiln Lane away from its target price, which drops to 11.6p, from 15p previously.

Pharma services group Ergomed (LON:ERGO) has announced the opening of a new office in Taiwan, which is the company's first office in Asia. 

Ergomed currently works with a number of Taiwanese companies and Stifel believes having on-the-ground support will be critical for gaining new clients in the area.

Ergomed currently trades at a 2015E P/E of 15.4 times, a 20% discount to its contract research peers. Buy says the broker.

Horizon Discovery (LON;HZD) has announced an OEM agreement with ArcherDX , a leader in Next Generation Sequencing (NGS) fusion detection.

Panmure Gordon expects Horizon to push ahead with commercial relationships and today's deal is only likely to be the first OEM agreement of many. ‘Buy’ is the view.


Register here to be notified of future ADM Company articles

No investment advice: The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use